Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer (PROLUT)

Central Hospital, Nancy, France

Status: Completed

Conditions: Prostate Cancer Metastatic

Treatments: Drug: 177Lu-PSMA-617

Study type: Observational

Funder types: Other

Identifiers

NCT06461689

2024PI106

Details and patient eligibility

About

To demonstrate the prognostic value of using post-therapy 177Lu-PSMA SPECT/CT versus 68Ga-PSMA-11 PET/CT in mCPRC patients progressing despite chemotherapy and treated with 177Lu-PSMA.

Full description

Since few years, therapy by 177Lu-PSMA in nancy hospital began. A lot's of datas were collected. Prostate cancer is the number one killer in france and this is very important to find a diagnostic tool.

The hypothesis of this study is to demonstrate the prognostic value of using post-therapy 177Lu-PSMA SPECT/CT versus 68Ga-PSMA-11 PET/CT in mCPRC patients progressing despite chemotherapy and treated with 177Lu-PSMA.

Enrollment: 80 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient who received a dose of 177lu-PSMA
• patient who had imaging by 68Ga-PSMA
• patient treated in Nancy hospital for its cancer prostate

Exclusion criteria

• no social security
• no acceptation to participating in retrospective study

Trial design

80 participants in 1 patient group

patient treated as part of mCPRC

Description:

All patients treated with 177Lu-PSMA had post-therapy 68Ga-PSMA PET and 177Lu-PSMA-617 SPECT/CT.

Treatment:

Drug: 177Lu-PSMA-617